PMV Pharmaceuticals, Inc.
NASDAQ:PMVPBiotechnology
Healthcare
$1.31 +3.91%
+$0.04 today
- Market cap
- $69.86M
- Beta
- 1.36
- P/E (TTM)
- -0.8
- EPS (TTM)
- -$1.47
52W Low $0.96High $1.88
Volume 1.19M
Average 0.38M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$86.21M
FY 2025 · Annual
Net Income
-$77.74M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 1.28M | 650K | 1.26M | 1.14M | 0 |
| Gross Profit | (1.28M) | (650K) | (1.26M) | (1.14M) | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 36.19M | 51.67M | 54.63M | 57.38M | 69.88M |
| Selling, General & Admin | 20.83M | 24.72M | 24.25M | 26.92M | 16.33M |
| Operating Expenses | 57.01M | 76.39M | 78.88M | 84.3M | 86.21M |
| Depreciation & Amortization | 1.28M | 650K | 1.26M | 1.14M | 133K |
| EBITDA | (56.54M) | (72.68M) | (67.7M) | (73.67M) | (79.78M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (58.29M) | (77.04M) | (80.13M) | (85.45M) | (86.21M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 449K | 3.63M | 11.17M | 10.66M | 6.34M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 470K | 3.71M | 11.17M | 10.64M | 6.29M |
| Income Before Tax | (57.82M) | (73.33M) | (68.96M) | (74.81M) | (79.91M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 23K | (9K) | 2K | (16.1M) | (2.17M) |
| Net Income | (57.85M) | (73.32M) | (68.96M) | (58.71M) | (77.74M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.28) | (1.61) | (1.44) | (1.14) | (1.48) |
| EPS (Diluted) | (1.28) | (1.61) | (1.44) | (1.14) | (1.48) |
| 45.14M | 45.59M | 48.01M | 51.58M | 52.54M | |
| 45.14M | 45.59M | 48.01M | 51.58M | 52.54M |
PMVP Earnings Waterfall · TTM
NASDAQ:PMVP · Revenue to Net Income
Key Ratios
EPS$-1.49
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-0.8
P/S Ratio0.0
Analysis
$0 of revenue converted into -$78.3M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.49, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 10, 2026 | |
| 10-Q | Quarterly report | Nov 10, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 5, 2026 | |
| 3 | Initial statement of beneficial ownership | Oct 5, 2026 | |
| 8-K | Current report | Oct 5, 2026 |
How much revenue does PMVP generate?
PMV Pharmaceuticals, Inc. (PMVP) reported $0.00 of revenue in fiscal 2025.
Is PMVP profitable?
PMV Pharmaceuticals, Inc. (PMVP) reported -$77.74M of net income.
Continue the stock analysis
Jump to another research area for this company.